Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07108114 · ClinicalTrials.gov registry record · Phase 1
SLV-324 Treatment of Metastatic Solid Tumors
A Phase 1 study of Metastatic Solid Tumors, sponsored by Solve Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 7
- Study locations
NCT07108114: Recruiting Phase 1 study of Metastatic Solid Tumors, sponsored by Solve Therapeutics.
NCT07108114 is a Phase 1 study of Metastatic Solid Tumors that is actively recruiting participants, run by Solve Therapeutics. The registered enrollment target is 70 participants, below the 203-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (66% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07108114, a Phase 1 study of Metastatic Solid Tumors, is actively recruiting participants, sponsored by Solve Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.
Primary Outcome
Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-324
Conditions Studied
Interventions
- DRUG SLV-324 intravenous (IV infusion)
Study Locations (7)
Texas
- MD Anderson Cancer Center - Houston
- Mays Cancer Center; University of Texas Health San Antonio - Houston
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Missouri
- Washington University - St Louis
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Washington
- University of Washington / Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What NCT07108114 shows while recruiting
NCT07108114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 203-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which SLV-324 intravenous (IV infusion) is the first listed.
NCT07108114 lists 7 locations in 6 states (Texas, California, Missouri).
Frequently Asked Questions
What is clinical trial NCT07108114 about?
NCT07108114 is a clinical study titled "SLV-324 Treatment of Metastatic Solid Tumors". This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.
What is the current status of trial NCT07108114?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2025-08-25. Estimated completion is 2027-08.
What conditions does trial NCT07108114 study?
This clinical trial studies the following conditions: Metastatic Solid Tumors.
What interventions are being tested in trial NCT07108114?
The interventions under investigation include: SLV-324 intravenous (IV infusion) (DRUG).
Who is sponsoring clinical trial NCT07108114?
This trial is sponsored by Solve Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07108114 being conducted?
This trial has 7 study locations across California, Missouri, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07108114's enrollment target sits among peer trials
70 15th of 20 higher than 6 of 20 other Metastatic Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
RECRUITING · Phase 1
-
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI